It is now out for the PUBLIC: the list of active ingredients of medicines with registration requests UNDER Anvisa REVIEW is NOW open!
In response to the sector's desires, to increase the transparency of its activities, Anvisa releases a public list that allows to consult the active ingredients of medicines with registration requests being analyzed by the Agency.
The new tool makes it possible to know the number of registration requests for each active ingredient. Includes generic, similar, specific, herbal, dynamic, biological, radiopharmaceutical and advanced therapy products.
Only requests for clone medicines are not included in the panel.
From the panel, interested parties will be able to identify all active ingredients of medicines, by regulatory category and quantity, submitted for evaluation by Anvisa, with no decision published yet. The dashboard will be updated monthly.
The disclosure of active ingredients was defined after a process of discussion with entities in the regulated sector and consultations with the Federal Attorney's Office, Anvisa and the Administrative Council for Economic Defense (CADE).
This initiative reflects Anvisa's commitment to transparency, in accordance with the 2011 Access to Information Law.
Publicity for this list has been requested for some time, as for the productive sector such information can optimize planning and investment in research and development of medicines and, consequently, meet health needs more efficiently.
Disclosing this information is very important as it allows decision-making to invest in development or define whether it is possible to prioritize a generic process or monitor market trends to develop a marketing strategy.
In conclusion, this transparency will bring a better balance to the supply of the medicines market, meeting Anvisa's objective of increasing operational efficiency, transparency and collaboration, always in support of the Agency's mission, which is the protection and promotion of health of the population by controlling the risks of products and services under health surveillance, in collaboration with the Unified Health System (SUS).
Consultation of already registered medicines continues to be available at https://consultas.anvisa.gov.br/#/medicamentos/.
Source: Anvisa
Comments